This reflected the potential effects of ER+/− status accuracy estimated by ESR1 expression, lymph-node status, co-existence of other dominant modulator genes in ovarian cancer, expression measurement (log-transform or not, RPKM or TPM, etc.), and characteristics of sample population on ER modulation as well as our model (see the Supplementary Discussion section). This evidence concerns the gene ESR1 and ovarian cancer.